REVErsing Airway Remodelling With Tezepelumab

PHASE3RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 27, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

June 1, 2026

Conditions
Airway Remodelling, Asthmatic
Interventions
DRUG

Tezepelumab

"Tezepelumab is supplied as a sterile, single-use, preservation-free, clear, colourless to slightly yellow liquid for subcutaneous administration in accessorized pre-filled syringes (APFS).~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."

OTHER

placebo

"APFS containing analogous placebo identical in appearance:~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."

Trial Locations (12)

Unknown

RECRUITING

CHU Dijon, Dijon

RECRUITING

CHU Grenoble Alpes La Tronche, Grenoble

RECRUITING

APHP Bicêtre, Le Kremlin-Bicêtre

WITHDRAWN

CHRU Lille, Lille

RECRUITING

Hôpital de la Croix Rousse, Lyon

RECRUITING

Hôpital Nord Marseille, Marseille

RECRUITING

CHU de Montpelier, Montpellier

RECRUITING

APHP Bichat, Paris

RECRUITING

Hôpital Foch, Paris

RECRUITING

Hôpital Haut-Lévêque, Pessac

RECRUITING

CHRU Strasbourg, Strasbourg

RECRUITING

CHU Toulouse, Toulouse

All Listed Sponsors
lead

University Hospital, Montpellier

OTHER